The "strong" guidance could help CRAY hit a new 52-week high when the market opens today (02012.02.28). Predicting Cray's business results is always difficult and almost every press release contains the phrase "While a wide range of results remains possible for ..."
[update::02012.02.28] It didn't happen until the end of the day, but CRAY did hit a new 52-week of $8.21 before closing at $8.20.
"The extension by Roche was expected. An extremely low number of shares have been tendered, consistent with our view – and that of our stockholders – that Roche’s offer does not reflect Illumina’s unique leadership position, business performance and future prospects. We remain focused on continuing to develop breakthrough products that expand existing markets and create new ones. The potential of our industry is enormous, with major new markets emerging in medical diagnostics, reproductive health and cancer management."ILMN closed last Friday (02012.02.24) at $51.22. 52-week range: $25.57 - $79.40
Geeknet (GKNT) hit a new 52-week low of $13.90 two days ago on 02012.02.22. GKNT closed yesterday (02012.02.23) at $14.63, which means our Geeknet investment is underwater. Where's the government bailout line?
Aastrom Biosciences (ASTM) hit a new 52-week low of $1.75 yesterday (02012.02.23). ASTM has been a frustrating investment and it is current underwater. The temptation to add to our position is strong and I might act on that temptation if ASTM falls to $1.50.
"Bruker is very well positioned to capitalize on strong demand tailwinds from a number of important secular trends, including accelerating shifts to post-genomic research and epigenetics, functional and imaging proteomics, structural biology, biologic drugs, a paradigm shift in clinical microbiology, protein and metabolite molecular diagnostics, fast and quantitative microscopy, 450 mm semiconductor FABs, shrinking semicon and nanotech feature sizes, and further adoption of superconductivity-enabled products in research, healthcare and energy/grid applications."
The following was also copied from Bruker's 4Q'11 press release.
"For the fourth quarter of 2011, Bruker’s cash flow from operations was $92.1 million, and free cash flow was $76.1 million. As of December 31, 2011, Bruker had cash, cash equivalents and restricted cash of $248.2 million and net debt of $54.9 million. As of December 31, 2011, Bruker’s Intangible Asset Ratio (IAR) was 13.8% and total debt leverage ratio was 1.2x."
~48% of BRKR shares are closely held. And, according to Bruker's "Key Statistics" page on Finance.Yahoo.com, institutions and mutual funds own 99% of BRKR's float.
Yesterday (02012.02.21) BRKR closed at $15.79. 52-week range: $11.48 - $21.65. BRKR was #8 in the GDT::Portfolio when the markets closed yesterday.
Nanosphere Announces Fourth Quarter and Full Year 2011 Results
Cash flow in the fourth quarter and third quarter of 2011 was negative $7.6 million. Cash at December 31, 2011 was $39.3 million.
There are approximately 37,800,000 NSPH shares. Cash per share is ~$1.04.
"We shipped 30 systems to new customers during the fourth quarter demonstrating an inflection point has been reached in our business. The investments we have made in menu expansion, particularly in the microbiology market segment, have generated significant customer interest and demand." -- William Moffitt, Nanosphere's president/CEO
"Inflection point" means 02012 is an important year for Nanosphere.
On 02012.02.03 (i.e. two weeks ago), NSPH hit an intra-day high of $2.13. Yesterday (02012.02.15) it closed at $1.79. 52-week range: $0.89 - $3.89
Eight days ago (2/8/02012) the following was one of my Facebook postings.
I just went through my Timeline to find this Facebook update from eight days ago (2/8/02012)... Interesting Moore's Law observation from Martin Ford's book "Lights in the Tunnel". The computers on Wall Street that help cause the 02007 economic meltdown had doubled in power by the time Martin wrote his book in 02009. It has been two years since Martin documented that observation and that means the power of Wall Street computers have doubled again.
NeuroMetrix (NURO) reported 4Q'11 results prior to the market opening today (02012.02.15). The company has significantly diluted the holdings of existing shareholders to raise cash to grow its medical device business to "diagnosis and treat the neurological complications of diabetes." From the 4Q'11 press release: "NeuroMetrix reported net cash consumption of $1.4 million in the fourth quarter of 2011 and ended the period with cash resources of $10.3 million." Earlier this month NeuroMetrix raised $7.5 million by floating more stock. NURO closed yesterday at $0.91. 52-week range: $0.89 - $3.78.
